Genmab A/S (GMAB)

NASDAQ: GMAB · USD

$57.5

+12.78 (+28.6%)· Recorded snapshot

Market cap	34.3B
Revenue (ttm)	4.1B
Net income (ttm)	788M
EPS (ttm)	$1.23
Shares out	59.7M
P/E (trailing)	46.6x
P/E (forward)	38.9x
Volume	28,520,148
Beta	0.65

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 4.1B
Net income (ttm): 788M
EPS (ttm): $1.23
P/E (trailing): 46.6x
P/E (forward): 38.9x
Market cap: 34.3B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	احتفاظ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E38.9

P25 13.4P50 20.2P75 35.7

Trailing P/E46.6

P25 15.4P50 25.8P75 43.5

ROE14

P25 -113.8P50 -46.5P75 -0.9

ROIC12.1

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All GMAB indicators

Market & fundamental data

Available fields

261

Groups with data

Currency

USD

Showing 261 of 261 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001434265
Company name	Genmab A/S
Country	Denmark
Country code	US
CUSIP number	372303206
Earnings date	2026-11-05
Employees	3,119
Employees change	480
Employees growth	18.19%
Enterprise value	$38B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1999
Industry	Biotechnology
Is primary listing	No
Is SPAC	No
ISIN number	US3723032062
Last 10-K release date	2026-02-17
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split date	2018-05-01
Last stock split type	Forward
Market cap	$34.3B
Market cap category	Large-Cap
Next earnings date	2026-11-05
Options	Yes
Price	$57.45
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	GMAB
Website	https://www.genmab.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	37x
Average P/E ratio (10Y)	41.3x
Average P/E ratio (3Y)	20.4x
Average P/E ratio (5Y)	30.26x
Earnings yield	2.15%
EV/Earnings	38.54x
EV/EBIT	22.77x
EV/EBITDA	22.05x
EV/FCF	34.95x
EV/Sales	7.35x
FCF / EV yield	2.86%
FCF yield	3.25%
Forward EV/Sales	5.85x
Forward P/E	38.89x
Forward P/S	5.14x
Graham number	20.98691
Graham upside	-61.51%
Lynch fair value	$23.31
Lynch upside	-57.25%
P/(FCF - SBC) ratio	37.44x
P/(OCF - SBC) ratio	36.32x
P/B ratio	4.48x
P/E ratio	46.58x
P/FCF ratio	30.72x
P/OCF ratio	29.96x
P/S ratio	6.46x
Price/EBITDA ratio	19.39x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	32.29%
EBITDA margin	33.33%
Effective tax rate	13.02%
FCF margin	21.04%
Gross margin	93.03%
Operating margin	32.29%
Pretax margin	21.93%
Profit margin	19.08%
Profit per employee	$252,645
Profitable quarters	34
Profitable years	9
Revenue per employee	$1.3M
ROA	8.79%
ROA (5Y)	10.27%
ROCE	11.73%
ROE	14%
ROE (5Y)	18.28%
ROIC	12.07%
ROIC (5Y)	66.47%
SBC / revenue	3.78%
Tax / revenue	2.86%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-36.79%
EPS growth (Q)	-9.41%
EPS growth (QoQ)	491.57%
EPS growth 10Y	22.48%
EPS growth 3Y	7.05%
EPS growth 5Y	15.83%
EPS growth years	0
FCF growth	-12.75%
FCF growth (Q)	-5.77%
FCF growth 3Y	1.65%
FCF growth 5Y	-0.57%
Gross profit growth	20.39%
Gross profit growth (Q)	23.39%
Gross profit growth 3Y	17.39%
Gross profit growth 5Y	26.91%
Net income growth	-37.9%
Net income growth (Q)	-9.82%
Net income growth (QoQ)	471.7%
Net income growth 3Y	5.02%
Net income growth 5Y	14.48%
Net income growth years	0
OCF growth	-14.08%
OCF growth (Q)	-17.74%
OCF growth (QoQ)	1,600%
OCF growth 10Y	26.01%
OCF growth 3Y	0.23%
OCF growth 5Y	-0.81%
Operating income growth	13.53%
Operating income growth (Q)	13.06%
Operating income growth 3Y	12.28%
Operating income growth 5Y	22.07%
Revenue growth	22.26%
Revenue growth (Q)	24.87%
Revenue growth (QoQ)	28.91%
Revenue growth 10Y	35%
Revenue growth 3Y	20.2%
Revenue growth 5Y	28.76%
Revenue growth quarters	20
Revenue growth years	4

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-22M
Depreciation and amortization	$43M
EBIT	$1.3B
EBITDA	$1.4B
EPS	$1.23
FCF per share	$14.56
Financing cash flow	$5B
Free cash flow	$869M
Free cash flow minus SBC	$713M
Gross profit	$3.8B
Income taxes	$118M
Investing cash flow	$-5.6B
Net borrowing	$5.4B
Net cash flow	$207M
Net income	$788M
Operating cash flow minus SBC	$735M
Operating income	$1.3B
Revenue	$4.1B
Stock-based compensation	$156M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.91
Book value per share	$99.78
Debt / EBITDA	3.78
Debt / equity	0.89
Debt / FCF	6.07
Goodwill	$355M
Interest coverage	4.96
Long-term assets	$9.7B
Long-term liabilities	$5.4B
Net cash (debt)	$-3.8B
Net cash / market cap	-14.09%
Net debt / EBITDA	2.73
Net debt / equity	0.63
Net debt / FCF	4.33
Piotroski F-Score	4
Property, plant and equipment	$254M
Shareholders' equity	$6B
Tangible book value	$-3.3B
Tangible book value per share	$-54.77
Total assets	$12.5B
Total cash	$1.5B
Total debt	$5.3B
Total liabilities	$6.6B
WACC	7.24%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.44
Current assets	$2.8B
Current liabilities	$1.1B
Current ratio	2.46
Inventory turnover	18.58
Net working capital	$463M
Quick ratio	2.44
Working capital	$1.7B
Working capital turnover	1.67

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	1.73%
Dividend yield	0%
Shareholder yield	1.73%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	242.14%
10Y return CAGR	13.09%
10Y total return	242.14%
150-day SMA	$30.44
1D price change	28.61%
1M price change	62.74%
1M total return	62.74%
1W price change	47.12%
1W total return	47.12%
1Y price change	98%
1Y return CAGR	98.1%
1Y total return	98%
20-day SMA	$39.44
200-day SMA	$30.28
3M price change	99.58%
3M total return	99.58%
3Y price change	102.25%
3Y return CAGR	26.46%
3Y total return	102.25%
50-day SMA	$36.20
50-day SMA vs 200-day SMA	50over200
52-week high	$59.97
52-week high date	2026-10-28
52-week low	$23.62
52-week low date	2026-06-03
5Y price change	27.17%
5Y return CAGR	4.93%
5Y total return	27.17%
6M price change	115.77%
6M total return	115.77%
All-time high	$59.97
All-time high date	2026-10-28
All-time low	$2.80
All-time low date	2013-06-24
Average true range (ATR)	$2.44
Average volume	6.2M
Beta (5Y)	0.65
Change from 52-week high	-4.2%
Change from 52-week low	143.23%
Change from all-time high	-4.15%
Change from all-time low	1,951.39%
Change from open	28.73%
Day's gap	-0.09%
Dollar volume	$1.6B
High price	$59.96
Low price	$44.43
Monthly RSI	79.04
Open price	$44.63
Position in 52-week range	83.84%
Premarket change	-0.02%
Premarket close	$44.67
Premarket price	$44.66
Premarket volume	5.5K
Previous close	$44.67
Price vs 150-day SMA	88.85%
Price vs 20-day SMA	45.75%
Price vs 200-day SMA	89.81%
Price vs 50-day SMA	58.78%
Relative volume	4.58
RSI	90.5
Sharpe ratio	1.64
Sharpe ratio (3Y)	0.66
Sharpe ratio (5Y)	0.19
Sortino ratio	3.55
Sortino ratio (3Y)	1.22
Sortino ratio (5Y)	0.46
Volume	28.5M
Weekly RSI	89.3
YTD price change	86.62%
YTD total return	86.62%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	55.3M
Float percentage	92.69%
Shares change (QoQ)	-3.36%
Shares change (YoY)	-1.73%
Shares held by insiders	1.21%
Shares held by institutions	62.62%
Shares outstanding	59.7M
Short % of shares	1%
Short ratio	2.7 days

Other indicators

Additional ticker metrics that do not fit the primary research groupings.

Metric	Value
Page views	740

Deeper analysis on GMAB

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this GMAB report

Is a complete GMAB research report available?

No complete published report is available for Genmab A/S (GMAB) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Genmab A/S (GMAB)

Price

Financial snapshot

Fair-value bridge

Latest news · GMAB

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All GMAB indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Other indicators

Deeper analysis on GMAB

Frequently asked questions